Since their arrival, GLP-1 weight-loss medicines have forced food manufacturers and restaurant groups to rethink products, portions and propositions, yet the long-term disruption they will cause remains uncertain.

The drugs have accelerated existing moves toward smaller servings and more nutrient-dense choices, creating new opportunities even as they expose brands to fresh risks. According to market analysis, the GLP-1-friendly foods boom is already substantial, with major players launching reformulated meals and snacks to match shifting appetite and nutritional priorities.

Speaking at The Food Institute’s Foodservice Summit, Circana senior vice-president David Portalatin put the phenomenon in perspective, arguing it is one of several dieting cohorts currently reshaping consumer behaviour.

“As a dieting cohort, [GLP-1 drug users] are slightly larger than keto, slightly smaller than intermittent fasting,” he said, suggesting the cohort is significant, but not monolithic. Portalatin cautioned companies against wholesale repositioning that could dilute brand identity.

Market data underpin that ambivalence: new GLP-1 prescriptions climbed year-on-year, reaching millions, yet analysts note the number of people who use the drugs actively month-to-month is substantially lower.

The Food Institute estimates that while many households will try a GLP-1 over a year, the core 30-day active user base sits in a single-digit percentage range, a pattern that should temper industry overreactions.

Public sentiment and practical barriers further complicate predictions. Recent polling indicates cost is not the primary reason most people avoid these medicines; many cite confidence in managing weight without drugs, worries about side effects, or lack of interest.

Other surveys show a rapid rise in reported use since 2024 but also persistent reluctance in large portions of the population, suggesting demand could plateau sooner than some forecasts expect.

Spending on GLP-1s has already had a macroeconomic footprint. Prescription counts and payer outlays rose steeply in recent years, with billions spent through public programmes and private insurance, while average per-prescription prices have remained high.

That rise in utilisation has fed headlines and policy debates about affordability and access, even as actual user penetration among people without diabetes stayed modest in earlier years.

Consumption patterns are shifting beyond the drug-taking subset. Industry figures show a modest year-on-year reduction in per-capita calories and a broader tilt toward foods perceived as more satiating or nutrient-rich, such as protein and fibre-focused vegetables, trends amplified by demographic ageing.

Analysts say GLP-1s contribute to that dynamic but do not fully explain it; many consumers were already trading calories for perceived quality and healthfulness.

“There are a lot of trends baked into this shift: calorie consumption is moving to nutrient-dense categories [e.g., meats and fiber-rich vegetables], sometimes lowering overall intake compared to carbs, and we’re part of an aging population,” Portalatin said.

For consumer-packaged goods companies and restaurateurs, the near-term playbook is practical: offer more portion variety, smaller pack formats at appealing price points and menu flexibilities that accommodate sharing or downsizing.

Firms that have invested in product innovation see a commercial upside from serving customers who eat less by volume but spend more on perceived quality and dining experiences, though regulatory scrutiny and the need for careful reformulation pose constraints.

The wider picture points to a cautious commercial strategy rather than a full-scale pivot. While GLP-1 medicines are reshaping some shopping baskets and meal occasions, industry data and public polling imply a slower, more complex transition than some alarmist accounts suggest.

Companies that adapt nimbly, keeping brand distinctiveness while offering right-sized choices and transparent value, are likeliest to benefit whether GLP-1 adoption accelerates or flattens.

Sign up here to get the latest grocery and food news each morning